Search Results

You are looking at 91 - 100 of 106 items for :

  • "microsatellite instability" x
Clear All
Full access

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook and Christopher Willett

colorectal cancer specimens to identify individuals who might have Lynch syndrome: immunohistochemical analysis for MMR protein expression, which is often diminished because of mutation, and analysis for microsatellite instability (MSI), which results from

Full access

Chunkit Fung, Sophie D. Fossa, Clair J. Beard and Lois B. Travis

. Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res 1999 ; 246 : 1 – 10 . 54 Robinson E Neugut AI . Clinical aspects of multiple primary neoplasms . Cancer Detect Prev 1989 ; 13 : 287 – 292 . 55

Full access

Katrina S. Pedersen, Kanwal Raghav and Michael J. Overman

screening recommendations currently exist. Much like colon cancer, however, HNPCC is responsible for approximately 5% to 10% of cancers. 28 , 29 Thus, routinely assessing all SBA tumors for deficient MMR (dMMR) gene expression or high microsatellite

Full access

Yvonne Bombard, Peter B. Bach and Kenneth Offit

syndrome is high based on the analytic performance of microsatellite instability (MSI) testing and DNA sequencing, respectively. 30 However, the analytic validity of the diagnostic sequencing and the Multiplex Ligation-Dependent Probe Amplification (MRC

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory and Deborah A. Freedman-Cass

options for patients with metastatic anal cancer who have progressed on first-line chemotherapy in the 2018 version of these guidelines. Microsatellite instability/mismatch repair testing is not required. Microsatellite instability is uncommon in anal

Full access

Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure and Marian L. Birkeland

Colangelo LH Fumagalli D . Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value . Clin Cancer Res 2012 ; 18 : 6531 – 6541 . 78. Douillard JY Rong

Full access

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian and Jillian L. Scavone

years before sporadic cancer. 12 Screening of the tumor for defective DNA mismatch repair (MMR) using immunohistochemistry and/or microsatellite instability (MSI) is used to identify which patients should undergo mutation testing for Lynch syndrome (see

Full access

Immune Checkpoint Inhibitors in Cancer Patients With Microsatellite Instability-High (MSI-H) Status: An Experience From Qatar El-Hadi Omar Nabil PharmD, BCOP, BSc Pharm, RPh Nasser Sahar BSc Pharm Gasim Mahmoud MSc Khanna Maneesh MD, FRCR Nashwan

Full access

Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Kazuki Sudo, Jeannelyn S. Estrella, Brian D. Badgwell, Prajnan Das, Aurelio Matamoros Jr, Shumei Song and Jaffer A. Ajani

(EBV)–containing GC (10%), in which PIK3CA alterations are common; tumors showing microsatellite instability (20%); “chromosomally unstable” (50%; most common); and “genomically stable” (20% contain diffuse histology and 30% have RHOA signaling

Full access

Paul F. Engstrom, Mara G. Bloom, George Daniel Demetri, Phillip G. Febbo, William Goeckeler, Marc Ladanyi, Bryan Loy, Kate Murphy, Michael Nerenberg, Paul Papagni, Mark Robson, Robert W. Sweetman, Sean Tunis, Jessica DeMartino and Jonathan K. Larsen

( ER/PR ), and for the Onco type DX test (Genomic Health, Inc., Redwood City, CA). Other clinical guidelines include recommendations for KRAS mutation , BRAF mutation, and microsatellite instability testing. The increased use and complexity of some